Newsroom

Oncology

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

August 20, 2024

Oncology

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

July 31, 2024

Oncology

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy

July 26, 2024

Oncology

CHMP adopts positive opinion for BALVERSA^® (erdafitinib) for the treatment of adult patients

Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers¹

The CHMP’s recommendation is based on results from Cohort 1 of the Phase 3 THOR study, which showed a 36 percent reduction in the risk of death with erdafitinib versus chemotherapy²

June 28, 2024

Oncology

Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer

Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab

Longer overall survival, progression-free survival and duration of response also observed with subcutaneous amivantamab

June 17, 2024

Oncology

TALVEY^® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

24-month overall survival rate of 67 percent achieved with TALVEY^® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study

June 14, 2024

Oncology

Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA^® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up

RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median progression-free survival of 8.9 years¹

Additional findings from pooled analysis of three Phase 3 studies showed treatment with ibrutinib has the potential to achieve comparable overall survival to the general European population²

June 14, 2024

Oncology

Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA^® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease

At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients¹

June 14, 2024

Oncology

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT^® clinical program

Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024

RYBREVANT^® marketing application submitted to European Medicines Agency based on PALOMA-3 study

June 3, 2024

Oncology

DARZALEX^® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO^® (daratumumab and hyaluronidase-fihj)-based induction, consolidation and maintenance regimens in the Phase 3 PERSEUS study

7.5 years median overall survival achieved with DARZALEX^®-based regimen in Phase 3 MAIA final analysis is the longest reported in patients ineligible for transplant

June 3, 2024

Newsroom

Press Releases

Discover J&J

Medicines & therapies

Medical devices & technology

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

About us

You are now leaving innovativemedicine.jnj.com

Key links

Get in touch

Search Results

No Results

Recently Viewed

Newsroom

Press Releases

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com